One recent clinical study found that the expression of BTNL2 and other immune checkpoint molecules, including CTLA-4, was increased following anti-PD-1 therapy, further suggesting that BTNL2 may represent a novel mechanism of cancer immune evasion48. Here, PDCD1 is linked to cancer.